Models and approaches for anti-TB drug testing

References

• Streptomycin treatment of pulmonary tuberculosis. Br. Med. J.2(4582), 769–782 (1948).
   PubMedGoogle Scholar
• Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q. J. Med.23(91), 347–366 (1954).
   PubMedGoogle Scholar
• Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. Br. Med. J.2(4688), 1073–1085 (1950).
   PubMedGoogle Scholar
• Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br. Med. J.2(4787), 735–746 (1952).
   PubMedGoogle Scholar
• Isoniazid in the treatment of pulmonary tuberculosis; second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br. Med. J.1(4809), 521–536 (1953).
   PubMedGoogle Scholar
• Emergence of bacterial resistance in pulmonary tuberculosis under treatment with isoniazid, streptomycin plus P.A.S. and streptomycin plus isoniazid. Lancet265(6779), 217–223 (1953).
   PubMedGoogle Scholar
• Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet1(7816), 1331–1338 (1973).
   PubMedGoogle Scholar
• Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle60(4), 201–210 (1979).
   PubMedGoogle Scholar
• East African/British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis: third report. Lancet304(7875), 237–240 (1974).
   Google Scholar
• Nitti V. Antituberculosis activity of rifampin. Report of studies performed and in progress (1966–1971). Chest61(6), 589–598 (1972).
   PubMed Web of Science ®Google Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis.3(10 Suppl. 2), S231–S279 (1999).
   PubMed Web of Science ®Google Scholar
• McClellan M. Drug safety reform at the FDA–pendulum swing or systematic improvement? N. Engl. J. Med.356(17), 1700–1702 (2007).
   PubMed Web of Science ®Google Scholar
• Temple RJ. Development of drug law, regulations, and guidance in the United States. In: Principles of Pharmacology: Basic Concepts and Clinical Applications. Munson PL, Mueller RA, Breese G (Eds). Chapman and Hall, New York, NY, USA, 1643–1663 (1995).
   Google Scholar
• Applications for FDA approval to market a new drug: adequate and well-controlled studies. 21 Code of Federal Regulations, Section 314.126, 151–153, US Government Printing Office, Washington DC, DC, USA (2010).
   Google Scholar
• Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis.147(4), 1062–1063 (1993).
   PubMed Web of Science ®Google Scholar
• Benator D, Bhattacharya M, Bozeman L et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet360(9332), 528–534 (2002).
   PubMed Web of Science ®Google Scholar
• Horne DJ, Royce SE, Gooze L et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis.10(6), 387–394 (2010).
   PubMed Web of Science ®Google Scholar
• Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.49(2), 627–631 (2005).
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis.190(9), 1642–1651 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta UD, Katoch VM. Animal models of tuberculosis. Tuberculosis (Edinb.)85(5–6), 277–293 (2005).
   PubMed Web of Science ®Google Scholar
• Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin. Respir. Crit Care Med.29(5), 542–551 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Nuermberger EL, Tasneen R et al. Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother.65(4), 729–734 (2010).
   PubMed Web of Science ®Google Scholar
• Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis.121(6), 939–949 (1980).
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol.61, 35–50 (2007).
   PubMed Web of Science ®Google Scholar
• Malik M, Drlica K. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob. Agents Chemother.50(8), 2842–2844 (2006).
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.47(2), 653–657 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.10(6), 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am. Rev. Respir. Dis.123(4 Pt 1), 367–371 (1981).
   PubMed Web of Science ®Google Scholar
• Floss HG, Yu TW. Rifamycin-mode of action, resistance, and biosynthesis. Chem. Rev.105(2), 621–632 (2005).
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother.43(4), 727–737 (1999).
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother.52(8), 2831–2835 (2008).
   PubMed Web of Science ®Google Scholar
• Dhillon J, Andries K, Phillips PPJ, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis90(5), 301–305 (2010).
   PubMed Web of Science ®Google Scholar
• Koul A, Vranckx L, Dendouga N et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Bio. Chem.283(37), 25273–25280 (2008).
   PubMed Web of Science ®Google Scholar
• Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother.39(11), 2484–2489 (1995).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother.52(5), 790–795 (2003).
   PubMed Web of Science ®Google Scholar
• Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr. Pharm. Des10(26), 3285–3295 (2004).
   PubMed Web of Science ®Google Scholar
• Botha FJ, Sirgel FA, Parkin DP, van de Wal BW, Donald PR, Mitchison DA. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S. Afr. Med. J.86(2), 155–158 (1996).
   PubMed Web of Science ®Google Scholar
• Burman WJ. The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment. Am. J. Respir. Crit Care Med.167(10), 1299–1301 (2003).
   PubMedGoogle Scholar
• Donald PR, Parkin DP, Seifart HI et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol.63(7), 633–639 (2007).
   PubMed Web of Science ®Google Scholar
• Diacon AH, Patientia RF, Venter A et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother.51(8), 2994–2996 (2007).
   PubMed Web of Science ®Google Scholar
• Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst. Rev. (4), CD005159 (2007).
   PubMedGoogle Scholar
• Sirgel FA, Botha FJ, Parkin DP et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J. Antimicrob. Chemother.32(6), 867–875 (1993).
   PubMed Web of Science ®Google Scholar
• Pheiffer C, Carroll NM, Beyers N et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int. J. Tuberc. Lung. Dis.12(7), 792–798 (2008).
   PubMedGoogle Scholar
• Loebel RO, Shorr E, Richardson HB. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J. Bacteriol.26(2), 167–200 (1933).
   PubMedGoogle Scholar
• Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis.13(11), 908–914 (1994).
   PubMed Web of Science ®Google Scholar
• Desjardin LE, Hayes LG, Sohaskey CD, Wayne LG, Eisenach KD. Microaerophilic induction of the α-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis.J. Bacteriol.183(18), 5311–5316 (2001).
   PubMedGoogle Scholar
• Yuan Y, Crane DD, Barry CE, III. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial α-crystallin homolog. J. Bacteriol.178(15), 4484–4492 (1996).
   PubMed Web of Science ®Google Scholar
• McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med.123(3), 445–468 (1966).
   PubMed Web of Science ®Google Scholar
• Rhoades ER, Frank AA, Orme IM. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung Dis.78(1), 57–66 (1997).
   PubMedGoogle Scholar
• Flynn JL, Capuano SV, Croix D et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb.)83(1–3), 116–118 (2003).
   PubMed Web of Science ®Google Scholar
• Smith DW, Balasubramanian V, Wiegeshaus E. A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle72(3), 223–231 (1991).
   PubMedGoogle Scholar
• Wallis RS, Wang C, Doherty TM et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis.10(2), 68–69 (2010).
   PubMed Web of Science ®Google Scholar
• Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis.99(1), 109–111 (1969).
   PubMedGoogle Scholar
• Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.12(2), 128–138 (2008).
   PubMed Web of Science ®Google Scholar
• Singh KK, Dong Y, Belisle JT, Harder J, Arora VK, Laal S. Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis. Clin. Diagn. Lab. Immunol.12(2), 354–358 (2005).
   PubMedGoogle Scholar
• Hu Y, Coates AR. Transcription of the stationary-phase-associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein. J. Bacteriol.181(5), 1380–1387 (1999).
   PubMed Web of Science ®Google Scholar
• Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio1(3), pii, e00139–10 (2010).
   Google Scholar
• Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis.119(4), 579–585 (1979).
   PubMed Web of Science ®Google Scholar
• Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am. Rev. Respir. Dis.143(4 Pt 1), 707–712 (1991).
   PubMedGoogle Scholar
• Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb.)88(Suppl. 1), S85–S92 (2008).
   PubMedGoogle Scholar
• Sacks LV, Behrman RE. Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb.)88(Suppl. 1), S93–S100 (2008).
   PubMedGoogle Scholar
• Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med.328(8), 527–532 (1993).
   PubMed Web of Science ®Google Scholar
• Telzak EE, Sepkowitz K, Alpert P et al. Multidrug-resistant tuberculosis in patients without HIV infection. N. Engl. J. Med.333(14), 907–911 (1995).
   PubMed Web of Science ®Google Scholar
• Rullan JV, Herrera D, Cano R et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg. Infect. Dis.2(2), 125–129 (1996).
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med.360(23), 2397–2405 (2009).
   PubMed Web of Science ®Google Scholar
• Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest117(3), 744–751 (2000).
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med.348(22), 2186–2195 (2003).
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Nahid P, Gonzalez LC, Rudoy I et al. Treatment outcomes of patients with HIV and tuberculosis. Am. J. Respir. Crit. Care Med.175(11), 1199–1206 (2007).
   PubMed Web of Science ®Google Scholar
• Sacks LV, Behrman RE. Challenges, successes and hopes in the development of novel TB therapeutics. Future Med. Chem.1(4), 749–756 (2009).
   PubMed Web of Science ®Google Scholar
• Yasinskaya Y, Plikaytis B, Sizemore C, Sacks L. Advancing the development of diagnostic tests and biomarkers. Int. J. Tuberc. Lung Dis.15(7), 985–987 (2011).
   PubMedGoogle Scholar
• Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother.54(8), 3402–3407 (2010).
   PubMed Web of Science ®Google Scholar